NICE rejects Inlyta(Pfizer) for treatment of Renal Cell Carcinoma
NICE, the healthcare guidance body, has issued draft guidance not recommending Inlyta (axitinib) from Pfizer, for the treatment of advanced Kidney Cancer.The preliminary decision by the independent Appraisal Committee is that axitinib should not be recommended for the treatment of advanced Renal Cell Carcinoma after failure of prior treatment with sunitinib or a cytokine. The trial data included a direct comparison of the drug to sofafenib, a drug not recommended by NICE. The trial also lacked a comparison to 'best supportive care', which is what the majority of patients receive now.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins